NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, Forecast & News

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) issued its quarterly earnings data on Tuesday, November, 12th. The technology company reported $1.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.10 by $1.87. The technology company earned $20.64 million during the quarter, compared to analyst estimates of $5.73 million. Opiant Pharmaceuticals had a negative return on equity of 7.39% and a net margin of 24.16%. View Opiant Pharmaceuticals' Earnings History.

Opiant Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Opiant Pharmaceuticals.

1 brokers have issued 12 month target prices for Opiant Pharmaceuticals' shares. Their forecasts range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 226.8% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.

News stories about OPNT stock have trended very positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of 3.1 on InfoTrie's scale. They also gave news coverage about the technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Opiant Pharmaceuticals.

Opiant Pharmaceuticals saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 15,800 shares, a decline of 46.3% from the December 31st total of 29,400 shares. Based on an average trading volume of 18,000 shares, the short-interest ratio is presently 0.9 days. Currently, 0.5% of the shares of the stock are sold short. View Opiant Pharmaceuticals' Current Options Chain.

Some companies that are related to Opiant Pharmaceuticals include Mountain Province Diamonds (MPVD), Jaguar Mining (JAGGF), Fission Uranium (FCUUF), Rubicon Minerals (RBYCF), Amerigo Resources (ARREF), Wealth Minerals (WMLLF), Santa Fe Gold (SFEG), Atlatsa Resources (ATLRF), Royal Standard Minerals Inc USA (RYSMF), Pacific Booker Minerals (PBMLF), Alderon Iron Ore (AXXDF), Bullfrog Gold (BFGC), Quantum Materials (QTMM), US Gold (USAU) and Dakota Territory Resource (DTRC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), Vodafone Group (VOD), Synchrony Financial (SYF), Cyberark Software (CYBR), Sangamo Therapeutics (SGMO) and Xilinx (XLNX).

Opiant Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.00%), Perritt Capital Management Inc. (0.88%), Wedge Capital Management L L P NC (0.55%), Advisor Group Inc. (0.16%), Advisory Services Network LLC (0.15%) and TCI Wealth Advisors Inc. (0.08%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas. View Institutional Ownership Trends for Opiant Pharmaceuticals.

OPNT stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Michael Sinclair, Phil Skolnick and Roger Crystal. View Insider Buying and Selling for Opiant Pharmaceuticals.

OPNT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Advisory Services Network LLC, TCI Wealth Advisors Inc., Tobias Financial Advisors Inc., Perritt Capital Management Inc. and Advisor Group Inc.. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, David D O'toole and Gabrielle Alison Silver. View Insider Buying and Selling for Opiant Pharmaceuticals.

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OPNT stock can currently be purchased for approximately $12.85.

Opiant Pharmaceuticals has a market capitalization of $52.56 million and generates $13.98 million in revenue each year. The technology company earns $-21,190,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.View Additional Information About Opiant Pharmaceuticals.

The official website for Opiant Pharmaceuticals is http://www.opiant.com/.

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]